Drug Profile
Lupus therapeutic - Eli Lilly and Company
Latest Information Update: 08 Apr 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lupus vulgaris
Most Recent Events
- 18 Sep 2013 Phase-I clinical trials in Lupus in USA (unspecified route)